IDH mutation and MGMT gene changes in glioblastoma: findings from a forward-looking patient registry

Tumors with both isocitrate dehydrogenase mutations and O6-methylguanine-DNA methyltransferase promoter methylation showed a median overall survival of 35.8 months for glioblastoma patients treated with Temozolomide and Radiation Therapy.

• Glioblastoma patients with both isocitrate dehydrogenase mutations and MGMT promoter methylation had the most favorable progression-free survival and overall survival.
• Patients with either isocitrate dehydrogenase mutations or MGMT promoter methylation exhibited intermediate outcomes.
• Wild type IDH1 glioblastomas with unmethylated MGMT promoter had the poorest survival outcomes.
• Treatment with Temozolomide plus Radiation Therapy improved overall survival and progression-free survival for wild type IDH glioblastomas compared to Radiation Therapy alone.
• Isocitrate dehydrogenase mutations appeared to confer resistance to Temozolomide, as shown by increased resistance in laboratory models.

Simplified